Filing Flows

Filing Flows › Companies › Aligos Therapeutics › Cash flow

Aligos Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$1.5M in Q3 2026 · −$68.4M over twelve months

Operating cash flow$1.5M
Free cash flow+$1.5M

Analysis

In Q3 2026, Aligos Therapeutics generated $1.5M of operating cash flow. That is $25.8M more than in Q3 2025 (−$24.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$68.4M; the largest uses were operating cash flow ($68.4M), net borrowing (+) / repaid (−) ($89K); besides operations, cash came from other investing ($57.8M), shares issued ($360K); the cash balance fell by $10.3M.

Operating cash flow was $1.5M against net income of −$21.9M. The largest differences: accrued liabilities −$3.5M, payables −$3.2M, prepaid and other assets +$1.5M.

Free cash flow

Aligos Therapeutics: free cash flow by quarterAligos Therapeutics: free cash flow by quarter−$18.4MQ4 2024−$20.9MQ1 2025−$15.5MQ2 2025−$24.3MQ3 2025−$21.7MQ4 2025−$23.1MQ1 2026−$24.9MQ2 2026$1.5MQ3 2026
Operating cash flow less capital spending.
Aligos Therapeutics: operating cash flow against capital spendingAligos Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$18.4M$0Q4 2024−$20.9M$0Q1 2025−$15.5M$0Q2 2025−$24.3M$0Q3 2025−$21.7M$0Q4 2025−$23.1M$0Q1 2026−$24.9M$0Q2 2026$1.5M$0Q3 2026
Latest (Q3 2026): Operating cash flow $1.5M, Capital spending $0.

Capital allocation, year by year

Aligos Therapeutics: where the cash came from (up) and went (down), by fiscal yearAligos Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$116MFY2021: Net borrowing −$79KFY2021: Capital spending −$892KFY2021FY2022: Operating cash flow −$79.4MFY2022: Net borrowing −$61KFY2022: Shares issued $205KFY2022: Capital spending −$943K$205KFY2022FY2023: Operating cash flow −$79.0MFY2023: Net borrowing −$96KFY2023: Shares issued $574KFY2023: Capital spending −$19K$574KFY2023FY2024: Operating cash flow −$80.7MFY2024: Net borrowing −$83KFY2024: Shares issued $436KFY2024: Capital spending −$130K$436KFY2024FY2025: Operating cash flow −$82.5MFY2025: Net borrowing −$14KFY2025: Shares issued $304K$304KFY2025
Over these 5 years operating cash flow totalled −$437M; the largest uses were operating cash flow ($437M) and capital spending ($2.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$31.1M
Debtnone
Net cash$31.1M
Cash runway5 months

Aligos Therapeutics is burning cash: its operations consume cash, a free cash flow of −$68.4M a year at the current rate against $31.1M of cash and investments: a runway of about 5 months before any new financing.

Where the cash came from and went

Aligos Therapeutics: sources (+) and uses (−) of cash, Q3 2026Aligos Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$1.5MCash drawn (+) / kept (−)−$1.3MOther investing−$127KNet borrowing (+) / repaid (−)−$8K
Aligos Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Aligos Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$68.4MOther investing$57.8MCash drawn (+) / kept (−)$10.3MShares issued$360KNet borrowing (+) / repaid (−)−$89KOther financing$2K

From profit to cash

Aligos Therapeutics: net income to operating cash flow, Q3 2026Aligos Therapeutics: net income to operating cash flow, Q3 2026Net income−$21.9MDepreciation & amortization$300KStock-based pay$1.3MPayables−$3.2MAccrued liabilities−$3.5MPrepaid and other assets$1.5MOperating cash flow$1.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$1.5M−$8K—−$1.3M$1.5M
Q2 2026−$24.9M−$16K—−$269K−$24.9M
Q1 2026−$23.1M−$62K—−$11.7M−$23.1M
Q4 2025−$21.7M−$3K$124K$23.6M−$21.7M
Q3 2025−$24.3M−$10K—−$23.3M−$24.3M
Q2 2025−$15.5M——$55.1M−$15.5M
Q1 2025−$20.9M——−$36.8M−$20.9M
Q4 2024−$18.4M−$43K$139K−$1.7M−$18.4M

Aligos Therapeutics: income statement and cash flow

Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%. The chart follows the revenue to costs, profit and cash.

Aligos Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.